Key facts
- Revalia Bio’s last known valuation is $35.3M (Oct 2024).
- It has raised $26.8M across 1 recorded rounds; the latest was Early Stage VC ($12.3M) in Oct 2024.
- Notable investors include Creative Destruction Lab, Connecticut Innovations, BoxOne Ventures, Sierra Ventures, Overmatch (Austin) — 11 tracked in total.
- Revalia Bio has filed 1 Form D with the SEC, most recently Nov 2024 ($12.3M sold to 32 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Revalia Bio
Funding rounds
1 roundsAbout Revalia Bio
Operator of a platform intended to redefine organ donation and reinvent drug development. The company specializes in biotechnology research through clinical trials without patients, personalizes care delivery, and precision drug targeting, enabling scientists, engineers, and innovators to build technologies that matter for patients.
- Sector
- Healthcare
- HQ
- West Haven, CT, United States
- Founded
- 2021
- Employees
- 26
- Website
- revaliabio.com/
- Ownership
- Privately Held (backing)
Revalia Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Revalia Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Revalia Bio in its N-PORT filings yet. We sweep new filings monthly.